What Is the Best Staging System for Hepatocellular Carcinoma in the Setting of Liver Transplantation?

作     者：Olthoff, Kim M. Forner, Alejandro Huebscher, Stefan Fung, John 

作者机构：Univ Penn Dept Surg Div Transplantat Philadelphia PA 19104 USA Univ Barcelona Barcelona Clin Liver Canc Grp Hosp Clin Barcelona August Pi I Sunyer Inst Biomed ResLiver Unit Barcelona Spain Network Ctr Biomed Res Hepat & Digest Dis Barcelona Spain Univ Birmingham Sch Canc Sci Birmingham W Midlands England Queen Elizabeth Hosp Dept Cellular Pathol Birmingham B15 2TH W Midlands England Transplant Ctr Dept Gen Surg Inst Digest Dis Cleveland OH USA 

出 版 物：《LIVER TRANSPLANTATION》 (肝移植)

年 卷 期：2011年第17卷第S2期

页      面：S26-S33页

核心收录：

学科分类：1002[医学-临床医学] 100210[医学-外科学(含：普外、骨外、泌尿外、胸心外、神外、整形、烧伤、野战外)] 10[医学] 

主　　题：Patients Staging Hepatocellular Cancer Human-centered computing Prognosis Transplantation patient history of liver transplantation Liver Transplantation 

摘      要：To assess the prognosis of all HCC patients, the beststaging system should take into account tumor stage,liver function, and physical status. In addition, theprognosis should be modified according to the *** is no worldwide consensus about the useof any HCC staging system for all HCC patients, andthe systems vary significantly by country. The TNMand Okuda staging systems are most commonly usedinternationally. The BCLC and CLIP staging systemsare used most frequently in Europe, whereas the JISsystem has been accepted as a standard in *** BCLC staging system is the only system thatlinks the prognosis with treatment recommendations,and it has been used in several major trials of HCCtherapy to define the patient population to berecruited and to stratify the patients into separateprognostic categories. It has been validated in severallarge patient populations around the world and hasbeen endorsed by several societies as a guide for clinicaldecision making. The sixth edition of the TNM systemis most widely used for determining a patient\ s prognosis after surgery or transplantation, and it hashigh predictive value after transplantation and *** has been validated in numerous patient populationsand forms the basis for many other stagingsystems and allocation policies. Unfortunately, thepathological TNM stage is not known before transplantation,and it plays an important role in determining posttransplant survival.